Before a medicine can be authorised for use, it must go through the clinical trials process to ensure that it is safe and effective and also that the quality of the product is sufficient.
This section contains information on every aspect of the clinical trials process.
12 October 2011: Guidance on risk-proportionate approaches to the management and monitoring of clinical trials has now been included in Appendix 2 of the MRC/DH/MHRA Joint Project document "Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products".
The unwanted display of the text is removed here...dont delete this
Risk adapted approaches to management of clinical trials
A risk proportionate approach to the initiation, management and monitoring of certain clinical trials is possible. This section provides further information, including details on how to submit via the clinical trial notification scheme.
The MHRA's Good Clinical Practice (GCP) Inspectorate is part of the Inspection, Standards and Enforcement Division of the MHRA. It assesses the compliance of organisations conducting clinical trials using investigational medicinal products with UK and EU legislation.
Good Manufacturing Practice (GMP) is that part of quality assurance which ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorisation (MA) or product specification.